New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 1, 2013
09:17 EDTMRK, AIXG, LXRX, RH, WAG, EDG, MYGN, BTN, PSTIOn The Fly: Pre-market Movers
HIGHER: Merck (MRK), up 3% after announcing restructuring plans, including intent to cut about 20% of workforce by end 2015... Lexicon (LXRX), up 21% after achieving positive clinical trial results for potential diabetes drug... Edgen Group (EDG), up 57% after agreeing to be acquired by Sumitomo Corp. for $12.00 per share... Myriad Genetics (MYGN), up 11% after Piper Jaffray says should be bought on any weakness and stock upgraded at Ladenburg... Ballantyne Strong (BTN), up 6% after acquiring Convergent Media Systems... Pluristem (PSTI), up 5% after PLX cells demonstrate efficacy in preclinical study for GvHD. LOWER: Walgreens (WAG), down 0.5% after Q4 earnings report... Aixtron (AIXG), down 4% after downgrade at Canaccord... Restoration Hardware (RH), down 3% after holder CP Home files to sell about 4M shares.
News For MRK;AIXG;LXRX;RH;WAG;EDG;MYGN;BTN;PSTI From The Last 14 Days
Check below for free stories on MRK;AIXG;LXRX;RH;WAG;EDG;MYGN;BTN;PSTI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 9, 2014
07:38 EDTWAGWalgreen pushed to boost buyback as Jana secures seats, Bloomberg says
Walgreen will most likely be pushed to increase a to $3B share buyback program that let down investors in August after Jana Partners reached an agreement on three board seats at the company, according to Bloomberg, citing a person familiar with the matter. Reference Link
07:11 EDTMYGNMyriad Genetics presented results from myPath Melanoma test clinical study
Subscribe for More Information
September 8, 2014
16:00 EDTMRKOptions Update; September 8, 2014
Subscribe for More Information
06:54 EDTWAGWalgreen appoints JANA's Barry Rosenstein to board of directors
Subscribe for More Information
05:50 EDTWAGStocks with implied volatility movement; DE WAG
Stocks with implied volatility movement; Deere (DE) 15, Walgreen (WAG) 30 according to iVolatility.
05:43 EDTPSTIPluristem Therapeutics advances to second cohort in PLX-PAD cells Phase I trial
Pluristem Therapeutics announced that its licensee, United Therapeutics Corporation, has completed the dosing of the first cohort of patients in its Phase I study using Pluristem's PLacental eXpanded, or PLX-PAD, cells in patients diagnosed with pulmonary arterial hypertension, or PAH. PAH, with a global market estimated at approximately $3B, is characterized by abnormally high blood pressure in the arteries of the lungs; it can disrupt lung and heart function, leading to debilitating conditions such as heart failure. The Phase I study, being conducted in Australia, is an open-label, dose-escalation study designed to enroll 9 patients diagnosed with PAH. The first cohort of 3 patients has received 0.5M PLX cells per kilogram body weight. An independent Data Safety Monitoring Board recommended advancement to the second cohort. The second cohort will receive 1M cells per kilogram, while the third cohort is planned to be administered 2M cells per kilogram. The primary endpoint of the study is the safety of PLX-PAD cells, which will be evaluated at 12 weeks and one year after dosing. Secondary efficacy endpoints are to be measured at six weeks post-treatment in order to assess changes in the ability to exercise, disease severity and cardio-respiratory function; measures include six-minute walk distance and cardio-pulmonary hemodynamic parameters evaluated via right heart catheterization and echocardiogram.
September 5, 2014
16:45 EDTMRKMarket ends week little changed after mixed economic data
Subscribe for More Information
12:42 EDTWAGStocks with increasing options volume
Stocks with increasing options volume: VALE MCP KORS WAG GM PCLN
11:47 EDTWAGOptions with increasing implied volatility
Subscribe for More Information
11:17 EDTMRKBristol-Myers files patent infringement suit against Merck
Subscribe for More Information
10:55 EDTWAGWalgreen call activity attributed to activist investor speculation
Subscribe for More Information
10:00 EDTWAGRumor: Walgreen strength attributed to activist investor speculation
Subscribe for More Information
08:39 EDTMRKMerck Keytruda sales to reach $5B in 2018, says BMO Capital
Subscribe for More Information
07:31 EDTWAGWalgreen notifies customers about label printing errors, WSJ reports
Walgreen has found that its systems were printing drug labels with random characters in the instructions during a recent system crash, making some hard to understand, and has reached out to notify thousands of customers about the issue, reported The Wall Street Journal, citing a company spokesman and an internal memo. Reference Link
September 4, 2014
15:16 EDTMRKMerck receives accelerated approval of Keytruda
Subscribe for More Information
09:02 EDTMRKMerck's relebactam granted QIDP, fast track designations by FDA
Merck announced that the U.S. Food and Drug Administration has designated relebactam -- previously known as MK-7655 -- the company’s investigational beta-lactamase inhibitor, as a Qualified Infectious Disease Product with designated Fast Track status. The QIDP and Fast Track designations apply to intravenous use of relebactam for the treatment of complicated urinary tract infections, complicated intra-abdominal infections and hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. Relebactam is an investigational, class A and C, beta-lactamase inhibitor that is being evaluated in combination with imipenem/cilastatin in ongoing Phase 2 clinical trials for the treatment of complicated urinary tract infections and complicated intra-abdominal infections. In preclinical studies, relebactam administered in combination with imipenem/cilastatin demonstrated antibacterial activity against a broad range of Gram-negative and beta-lactam-resistant pathogens. Merck plans to initiate Phase 3 studies with relebactam in combination with imipenem/cilastatin in 2015.
08:04 EDTWAGWalgreen reports total Q4 sales $19.06B, consensus $18.99B
Subscribe for More Information
08:03 EDTWAGWalgreen reports August SSS up 3.7%
Walgreens had August sales of $6.39B, an increase of 3.6% from $6.16B for the same month in fiscal 2013. Total front-end sales increased 2.1% in August compared with the same month in fiscal 2013, while comparable store front-end sales increased 1.4%. Customer traffic in comparable stores decreased 1.7% while basket size increased 3.1%.Prescriptions filled at comparable stores increased by 1.1% in August and increased 3.2% on a calendar day-shift adjusted basis. August 2014 had one additional Sunday and one fewer Thursday compared with August 2013. These calendar shifts negatively impacted prescriptions filled at comparable stores by 2.1 percentage points.
07:21 EDTMRKMedidata can obtain major new platform customers, says Stifel
Noting that Medidata (MDSO) partners with Veeva, Stifel believes that a number of Veeva (VEEV) customers could become Medidata platform customers, especially if they already use Medidata for R&D and clinical trial solutions. The firm identifies Merck (MRK), Gilead (GILD), and Teva (TEVA) as companies that may become platform clients for Medidata. Stifel keeps a $55 price target and Buy rating on Medidata.
06:03 EDTWAGStocks with implied volatility movement; WAG RAD
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use